Healthcare / Medical Instruments & SuppliesNYSE American
$1.63
-0.22 (-11.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-1.2M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-287.7%
↓Gross Margin
N/A
•Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-13.6M · FCF $-1.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-13.6M | $-13.6M | $4.8M | $-4.1M | $-1.4M |
| EBITDA | $-13.3M | $-13.3M | $5.0M | $-4.0M | $-1.4M |
| EPS | — | — | 0.92 | -0.81 | -0.29 |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | -0.12 | -0.17 | -0.15 |
| Current Ratio | 2.65 | 2.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.4M | $-1.4M | $-641000.00 | $-1.2M | $-1.5M |
| Returns | |||||
| ROE | -287.7% | -287.7% | -11.7% | 9.0% | 3.4% |
| Valuation | |||||
| P/B | 1.78 | 1.78 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 213.7% | -179.2% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-78.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.92 → n/d
Residual
-78.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.